Second tranche of Lanstead subscription shares

RNS Number : 0005I

Nuformix PLC

12 April 2022

 

12 April 2022

Nuformix plc

("Nuformix" or the "Company")

Second tranche of Lanstead subscription shares

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that further to the notifications of 14 December 2021 and 17 January 2022 relating to its subscription and associated sharing arrangements with Lanstead Capital Investors L.P. ("Lanstead"), application has now been made for trading on the Standard Segment of the Official List and the Main Market of the London Stock Exchange ("Admission") for the second tranche of the subscription, comprising 88,000,000 Ordinary Shares (the "Second Subscription Shares") for gross proceeds of £1,320,000 and the associated 5,700,000 Second Value Payment Shares.

Full details of the subscription and associated sharing agreements and the Second Value Payment Shares are set out in the earlier announcements referenced above.

Admission and dealings in the Second Subscription Shares and the Second Value Payment Shares, all of which will rank pari passu with the existing Ordinary Shares, are expected to commence at 8.00 am on 14 April 2022.

Total Voting Rights

Following Admission of the Second Subscription Shares and the Second Value Payment Shares the Company's enlarged issued share capital will comprise 709,309,368 Ordinary Shares with voting rights.  The figure of 709,309,368 Ordinary Shares may therefore be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Enquiries:

Nuformix plc
Dr Alastair Riddell, Executive Chairman	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	[phone]
John Howes (Corporate Broking)	[phone]
IFC Advisory Limited
Tim Metcalfe Zach Cohen	[phone] [e-mail]

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

 

END

 

 

IOEGPUCPCUPPGWG